Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 36.96 -2.45% -0.93
DCPH closed down 2.45 percent on Thursday, July 19, 2018, on 77 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical DCPH trend table...

Date Alert Name Type % Chg
Jul 19 Stochastic Reached Oversold Weakness 0.00%
Jul 19 Oversold Stochastic Weakness 0.00%
Jul 18 Oversold Stochastic Weakness -2.45%
Jul 17 Oversold Stochastic Weakness -2.40%
Jul 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.27%
Jul 16 Outside Day Range Expansion -3.27%
Jul 16 Oversold Stochastic Weakness -3.27%
Jul 13 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.60%
Jul 13 Stochastic Reached Oversold Weakness -1.60%
Jul 13 Oversold Stochastic Weakness -1.60%

Older signals for DCPH ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Is DCPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.61
52 Week Low 15.15
Average Volume 316,931
200-Day Moving Average 25.7473
50-Day Moving Average 34.882
20-Day Moving Average 39.2775
10-Day Moving Average 38.43
Average True Range 2.4022
ADX 14.91
+DI 17.4887
-DI 21.9298
Chandelier Exit (Long, 3 ATRs ) 37.9134
Chandelier Exit (Short, 3 ATRs ) 43.2266
Upper Bollinger Band 42.9655
Lower Bollinger Band 35.5895
Percent B (%b) 0.19
BandWidth 18.779199
MACD Line 0.4136
MACD Signal Line 1.1098
MACD Histogram -0.6962
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 31.9 Million
EPS -16.03
Price-to-Earnings (P/E) Ratio -2.31
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.32
Resistance 3 (R3) 40.38 39.32 39.76
Resistance 2 (R2) 39.32 38.46 39.29 39.57
Resistance 1 (R1) 38.14 37.94 37.61 38.08 39.39
Pivot Point 37.08 37.08 36.82 37.05 37.08
Support 1 (S1) 35.90 36.22 35.37 35.84 34.53
Support 2 (S2) 34.84 35.70 34.81 34.35
Support 3 (S3) 33.66 34.84 34.16
Support 4 (S4) 33.60